Compare Liberty Global Ltd Class C (LBTYK) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Global Ltd Class C vs Regeneron Pharmaceuticals Inc — how do they compare? Liberty Global Ltd Class C trades at $9.94 (market cap $3.47B), while Regeneron Pharmaceuticals Inc trades at $680.5 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 20.3× Liberty Global Ltd Class C's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals.
| LBTYK | REGN | |
|---|---|---|
Market Cap | $3.47B | $70.47B |
Sector | Technology | Health |
52-Week High | $12.67 | $812.27 |
52-Week Low | $10.00 | $545.46 |
Enterprise Value | $10.75B | $64.42B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LBTYK trades at $9.995, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $7.14 billion for 2025, though revenue grew to $4.88 billion. Recent news highlights strategic moves, including the planned 2027 Amsterdam listing of Ziggo Group. Analyst consensus is strongly positive, with 69% recommending Buy.
The outlook hinges on execution of the Ziggo Group spin-off, a potential value catalyst. However, persistent losses and high debt-to-asset ratio of 38.39% pose significant risks. The stock offers a deep value opportunity if management delivers on restructuring, but operational turnaround is critical for sustained recovery.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
